AR133135A1 - COMPOUNDS THAT MODULATE KRAS - Google Patents
COMPOUNDS THAT MODULATE KRASInfo
- Publication number
- AR133135A1 AR133135A1 ARP240101702A ARP240101702A AR133135A1 AR 133135 A1 AR133135 A1 AR 133135A1 AR P240101702 A ARP240101702 A AR P240101702A AR P240101702 A ARP240101702 A AR P240101702A AR 133135 A1 AR133135 A1 AR 133135A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- subject
- pharmaceutically acceptable
- need
- acceptable salt
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1). Un compuesto de la fórmula (1). Un método para inhibir una proteína KRAS G12D en un sujeto que lo necesita, el método comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de una cualquiera de las reivindicaciones 1 a 49, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de las reivindicaciones 50 o 51. Un método para elaborar un medicamento para tratar el cáncer en un sujeto que lo necesita, caracterizado porque se usa un compuesto de una cualquiera de las reivindicaciones 1 a 49, o una sal farmacéuticamente aceptable de este. Un método para elaborar un medicamento para inhibir la metástasis de cáncer en un sujeto que lo necesita, caracterizado porque se usa un compuesto de una cualquiera de las reivindicaciones 1 a 49, o una sal farmacéuticamente aceptable de este.A compound of formula (1). A compound of formula (1). A method of inhibiting a KRAS G12D protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claims 50 or 51. A method of making a medicament for treating cancer in a subject in need thereof, characterized in that a compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, is used. A method of making a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, is used.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063551426P | 2020-02-08 | 2020-02-08 | |
| US202363511484P | 2023-06-30 | 2023-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133135A1 true AR133135A1 (en) | 2025-08-27 |
Family
ID=96877912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101702A AR133135A1 (en) | 2020-02-08 | 2024-06-28 | COMPOUNDS THAT MODULATE KRAS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR133135A1 (en) |
-
2024
- 2024-06-28 AR ARP240101702A patent/AR133135A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092168A1 (en) | APPLICATION OF FAVIPIRAVIR IN THE TREATMENT OF CORONAVIRUS INFECTION | |
| ECSP066653A (en) | DERIVATIVES OF BENCENOSULFONILAMINO-PIRIDIN-2-IL AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (II-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | |
| AR127501A1 (en) | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | |
| AR127247A1 (en) | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | |
| MX2024009158A (en) | Parp7 inhibitors. | |
| AR127533A1 (en) | SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | |
| AR128257A1 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO STING ACTIVITY | |
| CO2026000093A2 (en) | Pharmaceutical compositions for nek7 kinase inhibitors | |
| MX2019004842A (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety. | |
| AR127496A1 (en) | CD73 COMPOUNDS | |
| CL2021003303A1 (en) | Treatment for synucleinopathies. | |
| CL2025001119A1 (en) | Cancer treatment methods using isoquinoline or 6-aza-quinoline derivatives | |
| AR133135A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| MX2022005199A (en) | SSAO INHIBITORS AND USE THEREOF. | |
| AR131842A1 (en) | METHODS FOR TREATING GLIOMAS | |
| AR133133A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| AR132408A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| AR129959A1 (en) | METHOD FOR TREATING DISEASES OR ORGANIC DISORDERS WITH ASK1 INHIBITORS | |
| AR126393A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF LIVER DISEASES | |
| AR133755A1 (en) | KRAS G12D MODULATION COMPOUNDS | |
| MX2024003112A (en) | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder. | |
| AR130282A1 (en) | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | |
| AR127582A1 (en) | METHODS FOR THE TREATMENT OF CANCER | |
| AR125934A1 (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
| AR132852A1 (en) | COMBITHERAPY TO TREAT CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |